SCHEMBL14720935

SCHEMBL14720935

CC(CCc1ccc(C(=O)O)cc1)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
RARB P10826 6/20 0.50
TSHR P16473 2/20 0.49
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
MAPT P10636 2/20 0.47
RARA P10276 1/20 0.47
MTOR P42345 1/20 0.47
GRIN2D O15399 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIN2B Q13224 1/20 0.46
GRIN2C Q14957 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HTT P42858 1/20 0.46
FOLH1 Q04609 1/20 0.45
MAPK1 P28482 1/20 0.45
TP53 P04637 1/20 0.44
RXRA P19793 1/20 0.44
RXRB P28702 1/20 0.44
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL104594 0.85 GRIN2D (0.57) ALDH1A1RARBTSHRKMT2AMEN1
SCHEMBL17590345 0.84 TSHR (0.45) TSHRKMT2AMEN1MAPTGRIN2D
SCHEMBL17590311 0.83 TSHR (0.50) ALDH1A1TSHRSMN1; SMN2POLBTDP1
SCHEMBL16080190 0.83 OPRK1 (0.50) TSHRKMT2AMEN1HTTFOLH1
SCHEMBL27500484 0.83 OPRK1 (0.50) TSHRKMT2AMEN1HTTFOLH1
SCHEMBL25181550 0.83 TSHR (0.50) ALDH1A1TSHRSMN1; SMN2POLBTDP1
SCHEMBL1073143 0.82 TSHR (0.68) ALDH1A1TSHRKMT2AMEN1SMN1; SMN2
SCHEMBL12670558 0.82 TSHR (0.68) ALDH1A1TSHRKMT2AMEN1SMN1; SMN2
SCHEMBL264775 0.82 TSHR (0.68) ALDH1A1TSHRKMT2AMEN1SMN1; SMN2
SCHEMBL9414680 0.82 MMP12 (0.54) ALDH1A1RARBTSHRKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9512155-B2 Chiral phosphines for palladium-catalyzed asymmetric α-arylation of ester enolates to produce tertiary stereocenters in high enantioselectivity NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2016-12-06 US disclosed
US-20150166586-A1 CHIRAL PHOSPHINES FOR PALLADIUM-CATALYZED ASYMMETRIC ALPHA-ARYLATION OF ESTER ENOLATES TO PRODUCE TERTIARY STEREOCENTERS IN HIGH ENANTIOSELECTIVITY NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2015-06-18 US disclosed
WO-2013028132-A9 CHIRAL PHOSPHINES FOR PALLADIUM-CATALYZED ASYMMETRIC ALPHA-ARYLATION OF ESTER ENOLATES TO PRODUCE TERTIARY STEREOCENTERS IN HIGH ENANTIOSELECTIVITY NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2013-08-22 WO disclosed
WO-2013028132-A1 CHIRAL PHOSPHINES FOR PALLADIUM-CATALYZED ASYMMETRIC ALPHA-ARYLATION OF ESTER ENOLATES TO PRODUCE TERTIARY STEREOCENTERS IN HIGH ENANTIOSELECTIVITY NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166586-A1 CHIRAL PHOSPHINES FOR PALLADIUM-CATALYZED ASYMMETRIC ALPHA-ARYLATION OF ESTER ENOLATES TO PRODUCE TERTIARY STEREOCENTERS IN HIGH ENANTIOSELECTIVITY EPHA8, DAGLA, TEC ALDH1A1 1570/4885RARB 3052/4885TSHR 1028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.